The results add to the growing evidence that the highly popular injection has broader health benefits for patients beyond treating Type 2 diabetes.

Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under the Ozempic and Wegovy brands. The Danish...

The world of biotech stocks offers a unique blend of high risk and potentially high reward. Companies operating in this space are constantly pushing the boundaries, making them primed investment op...

Novo Nordisk's widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, according to a large late-stage study.

At $1,300 a month, with limited supply, and side effects including nausea, vomiting and gastrointestinal maladies, there are plenty of reasons to find more cost-effective and appetizing ways to los...

Viking Therapeutics wowed the market with its latest phase 2 data. Its weight loss drug candidate might be better than the competition.

Yes, Oprah Winfrey is in the news again — in this case, for her decision to sell her stake in WW International WW, +8.33% (formerly known as WeightWatchers) and leave the company's board. The decis...

An analyst cranked his price target higher on the Danish pharmaceutical company. He increased it by 16%.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novo Nordisk had a near perfect FY23. Fundamentally, FY24 should look quite similar.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

While Ozempic is often affiliated with weight loss, the drug is not approved by the FDA for such a use. But its sibling treatment, Wegovy, is approved for chronic weight management in obesity patie...

The feverish craze for Wegovy, Ozempic and other GLP-1 drugs is not over. It is prompting food executives to call the top boss at Novo Nordisk to ask for advice.

Novo Nordisk's weight loss drug, Wegovy, shows potential for reducing cardiovascular risks by 20% in overweight or obese individuals. The company is actively working to scale up production of Wegov...

iShares MSCI Denmark ETF has benefited from weight loss drugs and has a weighting of 23% in the ETF. The EDEN ETF provides exposure to a wide range of Danish companies and is ideal for those lookin...